393 F.Supp.3d 5
D.D.C.2019Background
- Plaintiffs Bellion Spirits and Chigurupati sought TTB approval to advertise two specific health claims that NTX (an additive in vodka) "helps protect DNA from alcohol-induced damage" and "reduces alcohol-induced DNA damage."
- Bellion filed a petition with TTB (and a third party submitted COLAs for labels); TTB referred the evidence to FDA for scientific consultation and then denied all eight proposed health claims, finding them inadequately substantiated and misleading.
- TTB’s written denial adopted FDA’s assessment of the submitted studies, excluded many items as irrelevant or non-human/in vitro evidence, and explained why the remaining studies lacked dosage or long-term-data necessary to substantiate the claims.
- Bellion sued, alleging: (1) First Amendment commercial-speech restriction; (2) prior restraint via the COLA pre-approval process; (3) APA violation because TTB improperly delegated or rubber-stamped FDA; and (4) vagueness of the TTB standard.
- The Court applied deferential review to TTB’s factual and scientific findings (substantial-evidence standard) while reviewing legal and constitutional questions de novo; it denied Bellion’s attempt to add extra-record evidence.
- Holding: the Court granted summary judgment to the Government and denied Bellion’s motion — TTB lawfully consulted FDA, reasonably found the claims misleading/unsubstantiated, and the regulatory scheme survived APA, First Amendment, prior-restraint, and vagueness challenges.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| APA: Did TTB exceed statutory authority by consulting FDA or delegating scientific fact-finding? | TTB lacked statutory authority to involve FDA or unlawfully subdelegated final decisionmaking / rubber-stamped FDA without adequate review. | TTB acted within its statutory authority and regulations permit consultation; TTB retained final decisionmaking and sufficiently reviewed FDA input. | Held for Defendants: consultation was permitted; no unlawful delegation; TTB reasonably adopted FDA findings. |
| First Amendment (commercial speech): Are the DNA claims protected commercial speech and was their prohibition unconstitutional? | Claims are truthful; outright ban is excessive; a disclaimer would be less restrictive. | Claims are inherently or at least potentially misleading and may be banned; denial advances substantial interests (consumer protection, public health); disclaimer proposed was insufficient. | Held for Defendants: TTB reasonably found claims misleading (enough to ban); even under Central Hudson the restriction survives. |
| First Amendment (prior restraint): Is the COLA pre-approval scheme an unconstitutional prior restraint? | Pre-approval creates censorial discretion (vague standards, no timely response) and chills speech. | COLA targets commercial speech and uses objective standards; prior-restraint doctrine has limited application to commercial speech; COLA has a 90-day response rule. | Held for Defendants: prior-restraint analysis either inapplicable or satisfied; standards are sufficiently definite and COLA has permissible procedural limits. |
| Fifth Amendment (vagueness): Is the "adequately substantiated" standard void for vagueness? | Phrase gives no fair notice and permits arbitrary enforcement. | The regulation, guidance, and advisory procedures provide sufficient notice; TTB explained its application case-by-case. | Held for Defendants: standard is not impermissibly vague; agency provided adequate explanation and process. |
Key Cases Cited
- Central Hudson Gas & Elec. Corp. v. Pub. Serv. Comm’n, 447 U.S. 557 (framework for commercial-speech review)
- Motor Vehicle Mfrs. Ass’n v. State Farm Mut. Auto. Ins. Co., 463 U.S. 29 (arbitrary-and-capricious review standard)
- POM Wonderful LLC v. FTC, 777 F.3d 478 (D.C. Cir. 2015) (agency deceptive-advertising findings are factual and reviewed for substantial evidence)
- Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999) (evaluation of disclaimer and agency consideration of health-claim evidence)
- Rubin v. Coors Brewing Co., 514 U.S. 476 (addressing commercial-speech regulation on alcohol labeling)
- Zauderer v. Office of Disciplinary Counsel, 471 U.S. 626 (compelled disclosures in commercial speech context)
- Nutritional Health Alliance v. Shalala, 144 F.3d 220 (2d Cir. 1998) (upholding prior-approval regime for health claims on dietary supplements as sufficiently definite)
- City of Lakewood v. Plain Dealer Pub. Co., 486 U.S. 750 (prior-restraint concerns where officials have unbridled discretion)
- Near v. Minnesota ex rel. Olson, 283 U.S. 697 (landmark prior-restraint doctrine)